
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
From skin cancer drug studies to foot exams, patient and physician awareness of melanoma is key to quick detection of dreaded disease






